Regeneron, Sanofi deal

The companies partnered to jointly develop and commercialize immuno-oncology candidates, including PD-1 inhibitor REGN2810, and a pipeline of preclinical mAbs and bispecific antibodies. Regeneron began a Phase I trial of REGN2810 in 1Q15. The five-year deal may be extended by three years.

The pipeline includes products targeting lymphocyte-activation gene 3 ( LAG3; CD223) and glucocorticoid-induced tumor necrosis factor receptor (TNFR)-related protein (GITR; TNFRSF18) and bispecific antibodies to treat hematologic and solid cancers. The deal does not include chimeric antigen receptor (CAR) T cell therapies. ...